Research Interests:
My research interests are 1) to investigate the mechanisms of actions and resistance to anti-tubulin and anti-angiogenic agents in preclinical breast cancer models, 2) to identify molecular targets that play an important role in breast cancer subtypes, and investigation of the intervention of these targets as potential therapeutics in combination with classic breast cancer therapeutic agents that will eventually help design effective strategies in the clinic, 3) to establish novel human thymoma cell lines, characterize them at the molecular level and develop in vivo models.
Education and Training:
Postdoctoral Fellowship: University of Texas Medical Branch, Galveston, TX
Postdoctoral Fellowship: University of Tennesee, Memphis, TN
Ph.D.: Bosphorus University, Istanbul, Turkey
M.S.: Bosphorus University, Istanbul, Turkey
Recent Publications:
- Gokmen-Polar Y, Miller KD.
Redefining the target again: chemotherapeutics as vascular disrupting agents?
Cancer Cell. 2008 Sep 9;14(3):195-6.
- Bhati R, Gökmen-Polar Y, Sledge GW Jr, Fan C, Nakshatri H, Ketelsen D, Borchers CH, Dial MJ,
Patterson C, Klauber-DeMore N.
2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in
human breast cancer cells.
Cancer Res. 2007 Jan 15;67(2):702-8.
- Brown DPG, Gokmen-Polar Y, Jiang L, Tan J, Ringham H, Janecki DJ, Qi G, Witzmann
FA, Sledge GW, Jr., Wang M.
A comparative proteomic study to characterize the vinblastine resistance in human
ovarian cancer cells. Proteomics Clin Appl. 2007;1, 18-31.
- Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-
Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ.
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft
hormone refractory prostate cancer model.
Prostate. 2006 Oct 1;66(14):1498-511.
- Sledge GW Jr, Gökmen-Polar Y.
Protein kinase C-beta as a therapeutic target in breast cancer.
Semin Oncol. 2006 Jun;33(3 Suppl 9):S15-8.
- Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther
BD, Giannakakou P, Sledge GW Jr.
beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-
435 cancer cells.
Cancer Res. 2005 Oct 15;65(20):9406-14.
- Murray NR, Jamieson L, Yu W, Zhang J, Gökmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson
EA, Fields AP.
Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo.
J Cell Biol. 2004 Mar 15;164(6):797-802.
- Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS.
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Cancer Res. 2003 Jun 15;63(12):3425-9.
- Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP.
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.
Cancer Res. 2001 Feb 15;61(4):1375-81.
|
